<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04099589</url>
  </required_header>
  <id_info>
    <org_study_id>NCC2121</org_study_id>
    <nct_id>NCT04099589</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma</brief_title>
  <official_title>Multicenter Phase II Study of Gemcitabine/Cisplatin (GC) Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) in the Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Few previous studies focused on the neoadjuvant treatments of upper urinary or bladder
      cancer, especially chemotherapy combined with immunotherapy, however, available data of
      retrospective studies showed this neoadjuvant treatment model might benefit patients. So This
      prospective Phase II clinical trial was designed to explore the efficacy of chemotherapy
      combined with PD-1 inhibitor as neoadjuvant therapy in upper urinary and muscle-invasive
      bladder urothelial carcinoma, then to improve the rate of complete pathological remission,
      survival and provide medical evidence.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete response rate</measure>
    <time_frame>through study completion of 3 years</time_frame>
    <description>the percentage of pT0N0 patients after operations</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Upper Tract Urinary Carcinoma</condition>
  <condition>Muscle-invasive Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>MIBC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Muscle-invasive bladder cancer of T2-4aN0M0 confirmed by pathology after maximal transurethral resection of bladder tumors. Enrollment of 30 patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>UTUC Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upper tract urothelial carcinoma of T1-3N0M0 and high grade confirmed by flexible ureteroscope biopsy. Enrollment of 34 patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab</intervention_name>
    <description>Gemcitabine/Cisplatin plus Toripalimab</description>
    <arm_group_label>MIBC Group</arm_group_label>
    <arm_group_label>UTUC Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. bladder cancer of T2-4aN0M0

          2. upper tract urinary carcinoma of T1-3N0M0 and high grade

          3. ECOG 0-1

          4. good organ function

          5. no previous chemotherapy or immunotherapy

          6. Informed consent form signed

        Exclusion Criteria:

          1. unable to receive chemotherapy or surgery due to physical abnormalities

          2. previous cancer history

          3. active tuberculosis

          4. HIV

          5. autoimmune disease

          6. anticipating other clinical studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianzhong Shou, MD</last_name>
      <phone>13601332989</phone>
      <email>shoujzh@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jianzhong Shou</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>upper tract urinary carcinoma</keyword>
  <keyword>muscle-invasive bladder cancer</keyword>
  <keyword>neoadjuvant</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

